Gland Pharma Ltd updates on US FDA Inspection at Dundigal Facility, Hyderabad

Gland Pharma Limited has announced that following the Pre-Market Inspection covering US FDA's Quality System / Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) at the Company's Dundigal Facility at Hyderabad from 22nd August, 2022 to 25th August, 2022; the Company has received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, US FDA indicating closure of the inspection.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1577.00 as compared to the previous close of Rs. 1577.10. The total number of shares traded during the day was 6158 in over 1122 trades.

The stock hit an intraday high of Rs. 1589.50 and intraday low of 1572.35. The net turnover during the day was Rs. 9728062.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 PreMarketInspection USFDA DundigalFacility Hyderabad